Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.

Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

As of 2005, 83% of babies with critical congenital heart defects were expected to live past one year, up from 67% in 1993.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

The two-day event included talks on subjects ranging from how to best utilise AI to how to build a stable CRO.

Immunocore has dosed the first subject in the Phase I/II trial of IMC-R117C for treating colorectal and other gastrointestinal cancers.

A recent study carried out by researchers in Burkina Faso and the UK, and published in The Lancet Infectious Diseases, has shown that the first blood-stage malaria vaccine, RH5.1/Matrix-M, is safe, ...